Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin 500 mg for adults with mild to moderate COVID-19
PACTR202012892855610Not yet recruiting
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in coronavirus disease 2019 (COVID-19) comparing Artemisinin group with Standard of Care (2 arms). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
artemisinin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202012892855610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012892855610.